PACAP及其衍生物治疗糖尿病及其并发症的研究进展

doi:10.13523/j.cb.20180108

中国生物工程杂志

2018, Vol. 38

Issue (1): 62-68 DOI: 10.13523/j.cb.20180108

综述

PACAP及其衍生物治疗糖尿病及其并发症的研究进展

颜秋霞^1,²,马义¹(

),洪岸¹

1暨南大学细胞生物学系暨南大学生物医药研究院广东省生物工程药物重点实验室基因工程药物国家工程研究中心广州 510632
2 广州医科大学附属第六医院/清远市人民医院生殖医学中心清远 511518

Research Progress of Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) as a New Potential Therapeutic Peptide in Diabetes and Its Complications

Qiu-xia YAN^1,²,Yi MA¹(

),An HONG¹

1 Department of Cellular Biology of Jinan University, Institute of Biological Medicine of Jinan University, Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Guangzhou 510632, China
2 Center for Reproductive Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan 511518,China;

全文: PDF(706 KB) HTML

摘要：

垂体腺苷酸环化酶激活肽(PACAP)是近年新发现的神经多肽,属于促胰液素/胰高血糖素/血管活性肽(VIP)家族中的新成员,广泛分布于脑和外周组织器官,尤其在内分泌胰腺、性腺、呼吸和生殖系统,在能量代谢、神经保护、免疫系统等发挥重要生理学功能。糖尿病是一种常见的主要以高血糖为特征的慢性代谢性疾病,糖尿病并发症日益严重威胁着人们的身体健康,已成为导致糖尿病患者致死、致残的主要原因。主要对PACAP治疗糖尿病及其并发症国内外研究的最新进展进行论述。

关键词： 垂体腺苷酸环化酶激活肽; 糖尿病; 糖尿病并发症

Abstract:

Pituitary adenylate cyclase-activating polypeptide (PACAP) belongs to the secretin, glucagon, and vasoactive intestinal peptide(VIP) family. PACAP is widely distributed in the brain and peripheral organs, notably in the endocrine pancreas, gonads, respiratory and urogenital tracts. PACAP play important roles in metabolism and neuroprotection. Diabetes is a common chronic metabolic disease characterized by high blood sugar. Its complications have become the main cause of mortality and disability in diabetes patients. The knowledge accumulated over the past years on the role of this neuropeptide in diabetes and its major complications, particularly emphasizing its potential for new therapeutic approaches were outlined.

Key words: Pituitary adenylate cyclase-activating polypeptide (PACAP) Diabetes mellitus Diabetic complications

收稿日期: 2017-07-12 出版日期: 2018-01-31

ZTFLH:

Q819

基金资助: 广州市科技计划项目(201707010245);广东省自然科学基金面上项目(2015A030313333);广东省医学科研基金资助项目(B2014426)

作者简介: 通讯作者马义, 电子信箱: tmayi@jnu.edu.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	颜秋霞
	马义
	洪岸

引用本文:

颜秋霞,马义,洪岸. PACAP及其衍生物治疗糖尿病及其并发症的研究进展[J]. 中国生物工程杂志, 2018, 38(1): 62-68.

Qiu-xia YAN,Yi MA,An HONG. Research Progress of Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) as a New Potential Therapeutic Peptide in Diabetes and Its Complications. China Biotechnology, 2018, 38(1): 62-68.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20180108 或 https://manu60.magtech.com.cn/biotech/CN/Y2018/V38/I1/62

图1 PACAP的前体及其编码的生物活性肽的结构[3]

图2 PACAP在不同物种中高度保守[3]

图3 PACAP初级结构对受体识别、活化和选择性结合的结构域[3]

[1]	Miyata A,Arimura A,Dahl R R,et al.Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun, 1989, 164(1): 567-574. doi: 10.1016/0006-291X(89)91757-9
[2]	Guariguata L,Whiting D R, Hambleton I,et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract, 2014, 103(2): 137-149. doi: 10.1016/j.diabres.2013.11.002 pmid: 24630390
[3]	Vaudry D,Falluel A,Bourgault S,et al.Pituitary adenylate cyclase-activating polypeptide and its receptors:20 years after the discovery. Pharmacol Rev,2009, 61(3): 283-357. doi: 10.1124/pr.109.001370
[4]	Akesson L,Ahren B,Manganiello V C,et al.Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. Endocrinology,2003, 144(12): 5293-5299. doi: 10.1210/en.2003-0364 pmid: 12960103
[5]	Casanova L,Hughes F J,Preshaw P M.Diabetes and periodontal disease:a two-way relationship. Br Dent J,2014, 217(8): 433-437. doi: 10.1038/sj.bdj.2014.907 pmid: 25342350
[6]	Parker A,Meyer J,Lewitzky S,et al.A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. Diabetes,2001, 50(3): 675-680. doi: 10.2337/diabetes.50.3.675 pmid: 11246890
[7]	Yada T,Sakurada M,Filipsson K,et al.Intraperitoneal PACAP administration decreases blood glucose in GK rats,and in normal and high fat diet mice. Ann N Y Acad Sci,2000, 921(12): 259-263. doi: 10.1111/j.1749-6632.2000.tb06974.x pmid: 11193831
[8]	Nakata M,Yada T.Physiological and therapeutic roles of PACAP in glucose metabolism and diabetes. Nihon Yakurigaku Zasshi,2004, 123(4): 267-273. doi: 10.1254/fpj.123.267 pmid: 15056942
[9]	Sakurai Y,Shintani N,Hayata A,et al.Trophic effects of PACAP on pancreatic islets:a mini-review. J Mol Neurosci,2011, 43(1): 3-7. doi: 10.1007/s12031-010-9424-z pmid: 20645023
[10]	Yamamoto K,Hashimoto H,Tomimoto S,et al.Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes,2003, 52(5): 1155-1162. doi: 10.2337/diabetes.52.5.1155
[11]	Gray S L,Cummings K J,Jirik F R,et al.Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol,2001, 15(10): 1739-1747. doi: 10.1210/mend.15.10.0705 pmid: 11579206
[12]	Ahren B.Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. Neural Signaling:Opportunities for Novel Diagnostic Approaches and Therapies,2008, 1144(11): 28-35. doi: 10.1196/annals.1418.003 pmid: 19076360
[13]	Tsutsumi M,Claus T H,Liang Y,et al.A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes,2002, 51(5): 1453-1460. doi: 10.2337/diabetes.51.5.1453
[14]	Ma Y,Luo T J,Xu W N,et al.A new recombinant pituitary adenylate cyclase-activating peptide-derived peptide efficiently promotes glucose uptake and glucose-dependent insulin secretion. Acta Biochim Biophys Sin (Shanghai),2012, 44(11): 948-956. doi: 10.1093/abbs/gms078 pmid: 23052710
[15]	Ma Y,Ma M,Dai Y,et al.Expression, identification and biological effects of a novel VPAC2-specific agonist with high stability and bioactivity. Acta Biochim Biophys Sin (Shanghai),2010, 42(1): 21-29. doi: 10.1093/abbs/gmp106 pmid: 20043043
[16]	Ryu S,Ornoy A,Samuni A,et al.Oxidative stress in Cohen diabetic rat model by high-sucrose,low-copper diet:inducing pancreatic damage and diabetes. Metabolism,2008, 57(9): 1253-1261. doi: 10.1016/j.metabol.2008.04.021 pmid: 18702952
[17]	Castorina A,Giunta S,Mazzone V,et al.Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells. Peptides,2010, 31(12): 2276-2283. doi: 10.1016/j.peptides.2010.08.013 pmid: 20800633
[18]	St Hilaire R C,Murthy S N,Kadowitz P J,et al. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation. Peptides,2010, 31(8): 1517-1522. doi: 10.1016/j.peptides.2010.04.024 pmid: 20452385
[19]	Racz B,Gasz B,Borsiczky B,et al.Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen Comp Endocrinol,2007, 153(1-3): 115-123. doi: 10.1016/j.ygcen.2006.12.006 pmid: 17270184
[20]	Mazzocchi G,Malendowicz L K,Neri G,et al.Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland. Int J Mol Med,2002, 9(3): 233-243. doi: 10.3892/ijmm.9.3.233 pmid: 11836629
[21]	Akesson L,Ahren B,Edgren G,et al.VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology,2005, 146(2): 744-750. doi: 10.1210/en.2004-0504
[22]	Zhang X Y,Wang N L,Barile G R,et al.Diabetic retinopathy:neuron protection as a therapeutic target. Int J Biochem Cell Biol,2013, 45(7): 1525-1529. doi: 10.1016/j.biocel.2013.03.002 pmid: 23506699
[23]	Brownlee M.Biochemistry and molecular cell biology of diabetic complications. Nature,2001, 414(6865): 813-820. doi: 10.1038/414813a pmid: 1174241411742414
[24]	Gabriel R.Neuropeptides and diabetic retinopathy. Br J Clin Pharmacol,2013, 75(5): 1189-1201. doi: 10.1111/bcp.12003 pmid: 3635589
[25]	Giunta S,Castorina A,Bucolo C,et al.Early changes in pituitary adenylate cyclase-activating peptide,vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats. Peptides,2012, 37(1): 32-39. doi: 10.1016/j.peptides.2012.06.004 pmid: 22721946
[26]	Szabadfi K,Atlasz T,Kiss P,et al.Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell Tissue Res,2012, 348(1): 37-46. doi: 10.1007/s00441-012-1349-0 pmid: 22350850
[27]	Marzagalli R,Scuderi S,Drago F,et al.Emerging role of PACAP as a new potential therapeutic target in major diabetes complications. International Journal of Endocrinology,2015,(2015): 1-11. doi: 10.1155/2015/160928 pmid: 26074958
[28]	Szabadfi K,Szabo A,Kiss P,et al.PACAP promotes neuron survival in early experimental diabetic retinopathy. Neurochem Int,2014, 64(1): 84-91. doi: 10.1016/j.neuint.2013.11.005 pmid: 24262293
[29]	Seaborn T,Masmoudi-Kouli O,Fournier A,et al.Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. Curr Pharm Des,2011, 17(3): 204-214. doi: 10.2174/138161211795049679 pmid: 21348830
[30]	Scuderi S,D’Amico AG,Castorina A,et al. Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction. Peptides,2013, 39(1): 119-124. doi: 10.1016/j.peptides.2012.11.015 pmid: 23220033
[31]	Gnudi L.Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrol Dial Transplant,2012, 27(7): 2642-2649. doi: 10.1093/ndt/gfs121 pmid: 22584788
[32]	Banki E,Kovacs K,Nagy D,et al.Molecular mechanisms underlying the Nephroprotective effects of PACAP in diabetes. J Mol Neurosci,2014, 54(3): 300-309. doi: 10.1007/s12031-014-0249-z pmid: 24535559
[33]	Reglodi D,Kiss P,Horvath G,et al.Effects of pituitary adenylate cyclase activating polypeptide in the urinary system,with special emphasis on its protective effects in the kidney. Neuropeptides,2012, 46(2): 61-70. doi: 10.1016/j.npep.2011.05.001 pmid: 21621841
[34]	Banki E,Degrell P,Kiss P,et al.Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides,2013, 42(4): 125-130. doi: 10.1016/j.peptides.2013.02.002 pmid: 23416022
[35]	Calcutt N A,Cooper M E,Kern T S,et al.Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov,2009, 8(5): 417-429. doi: 10.1038/nrd2476 pmid: 19404313
[36]	Ma Y,Fang S X,Zhao S J,et al.A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions. Biomaterials,2015, 51(5): 80-90. doi: 10.1016/j.biomaterials.2015.01.064 pmid: 25771000
[37]	Yu R J,Wang J J,Li J,et al.A novel cyclopeptide from the cyclization of PACAP(1-5) with potent activity towards PAC1 attenuates STZ-induced diabetes. Peptides,2010, 31(6): 1062-1067. doi: 10.1016/j.peptides.2010.03.008 pmid: 20307608
[38]	Cheng H H,Ding Y,Yu R R,et al.Neuroprotection of a novel cyclopeptide CHSDGIC from the cyclization of PACAP (1-5) in cellular and rodent models of retinal ganglion cell apoptosis. PLoS One,2014, 9(10): e108090. doi: 10.1371/journal.pone.0108090 pmid: 4186886

[1]	唐德平,邢梦洁,宋文涛,姚慧慧,毛爱红. microRNA治疗在癌症及其他疾病中的研究进展^*[J]. 中国生物工程杂志, 2021, 41(11): 64-73.
[2]	陈飞,王晓冰,徐增辉,钱其军. 干细胞改善糖尿病的分子机制及临床研究进展[J]. 中国生物工程杂志, 2020, 40(7): 59-69.
[3]	陈庆宇,王鲜忠,张姣姣. 基因技术在治疗2型糖尿病中的应用^*[J]. 中国生物工程杂志, 2020, 40(11): 73-81.
[4]	冯琳晶,于洋,杜红伟. FoxO1在胰岛β细胞代谢灵活性受损及失代偿进程中的作用 ^*[J]. 中国生物工程杂志, 2018, 38(6): 70-76.
[5]	党诗莹,马义,文涛,肖兴,洪岸. 纳米复合肽SCM的制备及其对II型糖尿病治疗作用的研究 ^*[J]. 中国生物工程杂志, 2018, 38(5): 17-23.
[6]	孙一平, 王越, 金镇, 王晓岩, 孙磊, 张璇, 冯冲, 周效华. SHBG基因敲除小鼠模型的建立及其表型分析[J]. 中国生物工程杂志, 2017, 37(8): 39-45.
[7]	王得华, 马义, 韩磊, 肖兴, 李艳伟, 党诗莹, 范志勇, 文涛, 洪岸. 新型基因重组PACAP衍生物MPL-2的制备及其抗2型糖尿病作用研究[J]. 中国生物工程杂志, 2017, 37(5): 59-65.
[8]	王东波, 马义, 王孝丽, 赵绍军, 韩磊, 洪岸. 基因重组PACAP27衍生多肽RP2制备及促角膜上皮细胞增殖研究[J]. 中国生物工程杂志, 2015, 35(3): 61-65.
[9]	马义, 罗天杰, 洪岸. 新型重组VPAC2激动剂RD的制备及促进胰岛素功能的分子机制[J]. 中国生物工程杂志, 2014, 34(11): 60-66.
[10]	徐文娜, 马义, 叶祖禄, 罗天杰, 饶磊, 洪岸. 垂体腺苷酸环化酶激活肽衍生多肽RHMP的重组制备及促角膜损伤修复的初步研究[J]. 中国生物工程杂志, 2013, 33(2): 65-69.
[11]	杜彩贺, 胡芳, 魏婷婷, 张仁敏, 张红琳, 周东蕊, 陆祖宏. PCR-DGGE指纹图谱技术分析2型糖尿病模型小鼠胃微生物菌群结构[J]. 中国生物工程杂志, 2012, 32(03): 25-31.
[12]	袁凤山, 王长军, 董飞, 赵宇航. 诱导回输胰岛素分泌细胞对大鼠糖尿病的疗效[J]. 中国生物工程杂志, 2011, 31(5): 94-98.
[13]	袁凤山王长军董飞赵宇航. 诱导回输胰岛素分泌细胞对大鼠糖尿病的疗效[J]. 中国生物工程杂志, 2011, 31(05): 0-0.
[14]	刘延杰, 季虹, 林鲁霞, 臧学章, 宋长征, 荣海钦. Exendin-4的固相化学合成及鉴定[J]. 中国生物工程杂志, 2011, 31(02): 69-73.
[15]	宋文程金明飞李冬青赵丽芬张洪丹黄静吴自荣. 重组人GIP衍生物的克隆、表达、纯化及活性研究[J]. 中国生物工程杂志, 2010, 30(06): 38-43.

Viewed

Full text

Abstract

Cited

Shared

Discussed